[1] Lefevre MA, Nosbaum A. Dermpath and clinic: how to manage adverse reactions to biological agents[J]. Eur J Dermatol, 2021, 31(3):426-427. DOI: 10.1684/ejd.2021. 4070.
[2] Fritz AL, Lacy FA, Morrell DS. Angioedema: a potential complication of dupilumab in atopic dermatitis[J]. Pediatr Dermatol, 2021, 38(1):237-238. DOI: 10.1111/pde.14434.
[3] Treudler R, Delaroque N, Puder M, et al. Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema[J]. J Eur Acad Dermatol Venereol, 2021, 35(1):e30-e32. DOI: 10.1111/jdv.16782.
[4] Ludriksone L, Elsner P, Schliemann S. Acquired hypersensitivity to dupilumab: first case report[J]. J Eur Acad Dermatol Venereol, 2019, 33(12):e482-e483. DOI: 10.1111/jdv.15807.
[5] Phan M, Linfante A, Kroger K. Ulcerative injection-site reaction associated with dupilumab therapy[J]. JAAD Case Rep, 2020, 6(12):1350-1352. DOI: 10.1016/j.jdcr.2020. 09.022.
[6] Shirley M. Dupilumab: first global approval[J]. Drugs, 2017, 77(10):1115-1121. DOI: 10.1007/s40265-017- 0768-3.
[7] Matsunaga K, Katoh N, Fujieda S, et al. Dupilumab: basic aspects and applications to allergic diseases[J]. Allergol Int, 2020, 69(2):187-196. DOI: 10.1016/j.alit.2020. 01.002.
[8] Jackson K, Bahna SL. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases[J]. Expert Rev Clin Immunol, 2020, 16(3):311-319. DOI: 10.1080/1744666X.2020.1724089.
[9] Bian S, Zhang P, Li L, et al. Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US Food and Drug Administration Adverse Event Reporting System[J]. Front Pharmacol, 2021, 12:767999. DOI: 10.3389/fphar. 2021.767999.
[10] Singh SK, Mahler HC, Hartman C, et al. Are injection site reactions in monoclonal antibody therapies caused by polysorbate excipient degradants?[J]. J Pharm Sci, 2018, 107(11):2735-2741. DOI: 10.1016/j.xphs.2018.07.016.
[11] Pichler WJ. Adverse side-effects to biological agents[J]. Allergy, 2006, 61(8):912-920. DOI: 10.1111/j.1398-9995. 2006.01058.x.
[12] Galvão VR, Castells MC. Hypersensitivity to biological agents-updated diagnosis, management, and treatment[J]. J Allergy Clin Immunol Pract, 2015, 3(2):175-185; quiz 186. DOI: 10.1016/j.jaip.2014.12.006.
|